Automatic vein wall disruption, triggering the body’s natural cellular healing response to close targeted veins curing Venous Leg Ulcersbroad
EnVena · Horizon Europe grant · 2022-10-01–2024-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Chronic venous disease is one of the most common diseases in the developed world, affecting up to 60% of adults over the age of 50. Chronic venous disease is the leading cause of Venous Leg Ulcers which are chronic open sores, usually on the inside of the leg that will not heal without specialist treatment. The total costs associated with managing venous disease patients across Europe and the US is €33.4 billion per year, representing 2.5% of total healthcare expenditure.Most patients are treated with ineffective compression bandaging which does not treat the underlying cause and has an unacceptably high recurrence rate. These bandages are also sent to landfill with a high environmental impactEnVena is the world’s first device to mimic the body’s natural healing response to deliver an effective treatment to venous leg ulcer patients.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| INVERA MEDICAL LIMITED | IE | coordinator | €2,497,614 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.